Sangamo Therapeutics to Release Q4 2025 Earnings

The biotech firm is set to report financial results on Monday, March 16th.

Mar. 15, 2026 at 5:24am

Got story updates? Submit your updates here. ›

Sangamo Therapeutics (NASDAQ:SGMO), a clinical-stage biotechnology company focused on developing genomic therapies, is scheduled to release its fourth quarter 2025 financial results before the market opens on Monday, March 16th. Analysts expect the company to report earnings of $0.01 per share and revenue of $40.25 million for the quarter.

Why it matters

As a leading player in the genomic medicine space, Sangamo's quarterly earnings provide insight into the progress and performance of its pipeline of gene editing and gene regulation therapies targeting serious genetic and rare diseases. The company's financial results and updates on its clinical programs are closely watched by investors and the broader biotech industry.

The details

Sangamo Therapeutics is a clinical-stage biotechnology company headquartered in Brisbane, California that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. The company is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.

  • Sangamo Therapeutics is scheduled to release its Q4 2025 financial results before the market opens on Monday, March 16th, 2026.
  • The company's Q4 2025 earnings call is set for Thursday, March 19th, 2026 at 4:00 PM ET.

The players

Sangamo Therapeutics

A clinical-stage biotechnology company headquartered in Brisbane, California that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology.

Luminus Management LLC

An institutional investor that has increased its stake in Sangamo Therapeutics, now owning 1,158,761 shares.

Oracle Investment Management Inc.

An institutional investor that has increased its stake in Sangamo Therapeutics, now owning 1,035,742 shares.

Invesco Ltd.

An institutional investor that has increased its stake in Sangamo Therapeutics, now owning 1,000,292 shares.

Boothbay Fund Management LLC

An institutional investor that has increased its stake in Sangamo Therapeutics, now owning 353,292 shares.

Got photos? Submit your photos here. ›

What’s next

Investors can check the company's upcoming Q4 2025 earnings summary page for the latest details on the earnings call scheduled for Thursday, March 19, 2026 at 4:00 PM ET.

The takeaway

As a leader in genomic medicine, Sangamo Therapeutics' quarterly financial results and updates on its clinical pipeline are closely watched by the biotech industry and investors. The company's ability to advance its gene editing and gene regulation therapies through clinical trials will be a key focus area for the upcoming earnings report.